612 reports of this reaction
1.6% of all VALPROATE SODIUM reports
#10 most reported adverse reaction
CONVULSION is the #10 most commonly reported adverse reaction for VALPROATE SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 612 FDA adverse event reports linking VALPROATE SODIUM to CONVULSION. This represents approximately 1.6% of all 37,274 adverse event reports for this drug.
Patients taking VALPROATE SODIUM who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is a less commonly reported adverse event for VALPROATE SODIUM, but still significant enough to appear in the safety profile.
In addition to convulsion, the following adverse reactions have been reported for VALPROATE SODIUM:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 612 FDA reports for VALPROATE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 1.6% of all adverse event reports for VALPROATE SODIUM, making it a notable side effect.
If you experience convulsion while taking VALPROATE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.